KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) EBITDA: 2009-2025

Historic EBITDA for Bausch Health Companies (BHC) over the last 17 years, with Sep 2025 value amounting to $619.0 million.

  • Bausch Health Companies' EBITDA rose 94.65% to $619.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 40.52%. This contributed to the annual value of $1.5 billion for FY2024, which is 60.54% up from last year.
  • Latest data reveals that Bausch Health Companies reported EBITDA of $619.0 million as of Q3 2025, which was up 39.41% from $444.0 million recorded in Q2 2025.
  • Over the past 5 years, Bausch Health Companies' EBITDA peaked at $619.0 million during Q3 2025, and registered a low of -$270.0 million during Q2 2021.
  • For the 3-year period, Bausch Health Companies' EBITDA averaged around $349.8 million, with its median value being $362.0 million (2023).
  • Over the last 5 years, Bausch Health Companies' EBITDA had its largest YoY gain of 7,440.00% in 2021, and its largest YoY loss of 900.00% in 2021.
  • Over the past 5 years, Bausch Health Companies' EBITDA (Quarterly) stood at $367.0 million in 2021, then plummeted by 164.31% to -$236.0 million in 2022, then soared by 253.39% to $362.0 million in 2023, then spiked by 54.14% to $558.0 million in 2024, then skyrocketed by 94.65% to $619.0 million in 2025.
  • Its EBITDA was $619.0 million in Q3 2025, compared to $444.0 million in Q2 2025 and $276.0 million in Q1 2025.